2119 related articles for article (PubMed ID: 27156933)
1. Gastric cancer.
Van Cutsem E; Sagaert X; Topal B; Haustermans K; Prenen H
Lancet; 2016 Nov; 388(10060):2654-2664. PubMed ID: 27156933
[TBL] [Abstract][Full Text] [Related]
2. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Fuchs CS; Tomasek J; Yong CJ; Dumitru F; Passalacqua R; Goswami C; Safran H; Dos Santos LV; Aprile G; Ferry DR; Melichar B; Tehfe M; Topuzov E; Zalcberg JR; Chau I; Campbell W; Sivanandan C; Pikiel J; Koshiji M; Hsu Y; Liepa AM; Gao L; Schwartz JD; Tabernero J;
Lancet; 2014 Jan; 383(9911):31-39. PubMed ID: 24094768
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
Garrido M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
[TBL] [Abstract][Full Text] [Related]
4. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
5. Ramucirumab: first global approval.
Poole RM; Vaidya A
Drugs; 2014 Jun; 74(9):1047-58. PubMed ID: 24916147
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
Tehfe M; Tabchi S; Laterza MM; De Vita F
Future Oncol; 2018 Feb; 14(3):223-228. PubMed ID: 29318901
[TBL] [Abstract][Full Text] [Related]
7. [Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1].
Lévêque I; Spitzer E
Bull Cancer; 2024 Feb; 111(2):130-132. PubMed ID: 38071114
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
10. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
11. Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
Khan U; Shah MA
Expert Opin Biol Ther; 2019 Nov; 19(11):1135-1141. PubMed ID: 31452409
[No Abstract] [Full Text] [Related]
12. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
[TBL] [Abstract][Full Text] [Related]
13. Gastric Carcinoma at the Era of Targeted Therapies.
Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
[TBL] [Abstract][Full Text] [Related]
14. Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma.
Hofheinz RD; Lorenzen S
Expert Rev Anticancer Ther; 2015 Jun; 15(6):607-14. PubMed ID: 26035718
[TBL] [Abstract][Full Text] [Related]
15. Ramucirumab: A Review in Advanced Gastric Cancer.
Greig SL; Keating GM
BioDrugs; 2015 Oct; 29(5):341-51. PubMed ID: 26341713
[TBL] [Abstract][Full Text] [Related]
16. HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge.
Hicks DG; Whitney-Miller C
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):506-8. PubMed ID: 22089490
[TBL] [Abstract][Full Text] [Related]
17. Changes in the therapeutic landscape of oesophago-gastric cancers.
Fokter Dovnik N; Smyth EC
Curr Opin Oncol; 2021 Jul; 33(4):362-367. PubMed ID: 33720069
[TBL] [Abstract][Full Text] [Related]
18. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Janjigian YY; Kawazoe A; Yañez P; Li N; Lonardi S; Kolesnik O; Barajas O; Bai Y; Shen L; Tang Y; Wyrwicz LS; Xu J; Shitara K; Qin S; Van Cutsem E; Tabernero J; Li L; Shah S; Bhagia P; Chung HC
Nature; 2021 Dec; 600(7890):727-730. PubMed ID: 34912120
[TBL] [Abstract][Full Text] [Related]
19. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
Maron SB; Catenacci DVT
Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
[TBL] [Abstract][Full Text] [Related]
20. HER2 directed therapy for gastric/esophageal cancers.
Won E; Janjigian YJ; Ilson DH
Curr Treat Options Oncol; 2014 Sep; 15(3):395-404. PubMed ID: 24811128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]